Skip to content
value.today

Kolon TissueGene, Inc.

Total raised
$125 M
4 rounds on record
Latest round
$35 M
May 2024
First round on record
Dec 2021
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kolon TissueGene, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$35 MNo. 4$10 to $50 million

Kolon TissueGene, Inc.: Raise no. 4, May 2024

Investors in this round

1 investor had bought by the notice of Jun 5, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Joon Nye · Executive Officer
  • Diana Halim · Executive Officer
  • Gun Young Joon Park · Executive Officer
  • Jung In Kim · Executive Officer, Director
  • Moon Jong Noh · Executive Officer, Director
  • Soon-Wook Joon Kweon · Executive Officer
  • Sun Jin Joon Kim · Executive Officer
  • Yonggyun Joon Jeong · Executive Officer
  • Young Joon Kim · Executive Officer
  • Sun Joo Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Based on exchange rate quoted on May 22, 2024 by Seoul Money Brokerage Services (Seoul Oegukwan Junggae)”

Signed by Moon Jong Noh, President/CEO. Source: SEC Form D, newest notice filed Jun 5, 2024. Read the notice at the SEC.

equitySEC
May 2023$30 MNo. 3$10 to $50 million

Kolon TissueGene, Inc.: Raise no. 3, May 2023

Investors in this round

1 investor had bought by the notice of May 15, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Stephen Nye · Executive Officer
  • Diana Stephen Halim · Executive Officer
  • Gun Young Stephen Park · Executive Officer
  • Jung In Su Kim · Executive Officer, Director
  • Moon Jong Su Noh · Executive Officer, Director
  • Soon-Wook Joon Kweon · Executive Officer
  • Sun Jin Joon Kim · Executive Officer
  • Sung Su Han · Executive Officer, Director
  • Yonggyun Joon Jeong · Executive Officer
  • Young Joon Kim · Executive Officer
  • Sun Joo Su Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Moon Jong Noh, Co-President/Co-CEO. Source: SEC Form D, newest notice filed May 15, 2023. Read the notice at the SEC.

equitySEC
Aug 2022$30 MNo. 2$10 to $50 million

Kolon TissueGene, Inc.: Raise no. 2, Aug 2022

Investors in this round

2 investors had bought by the notice of Aug 29, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Stephen Nye · Executive Officer
  • Jung In Su Kim · Executive Officer, Director
  • Moon Jong Su Noh · Executive Officer, Director
  • Soon-Wook Joon Kweon · Executive Officer
  • Sun Jin Joon Kim · Executive Officer
  • Sung Su Han · Executive Officer, Director
  • Yonggyun Joon Jeong · Executive Officer
  • Young Joon Kim · Executive Officer
  • Jangik Su Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Moon Jong Noh, Co-President/Co-CEO. Source: SEC Form D, newest notice filed Aug 29, 2022. Read the notice at the SEC.

equitySEC
Dec 2021$30 MNo. 1$10 to $50 million

Kolon TissueGene, Inc.: Raise no. 1, Dec 2021

Investors in this round

2 investors had bought by the notice of Dec 16, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Stephen Nye · Executive Officer
  • Min Seok Su Kim · Executive Officer, Director
  • Moon Jong Su Noh · Executive Officer, Director
  • Soon-Wook Joon Kweon · Executive Officer
  • Sun Jin Joon Kim · Executive Officer
  • Sung Su Han · Executive Officer, Director
  • Yonggyun Joon Jeong · Executive Officer
  • Young Joon Kim · Executive Officer
  • Jangik Su Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Moon Jong Noh, Co-President/Co-CEO. Source: SEC Form D, newest notice filed Dec 16, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kolon TissueGene, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2024

That is all the official record says: Kolon TissueGene, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kolon TissueGene, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kolon TissueGene, Inc.
NameRoleNamed in
Charles Joon NyeExecutive officerJun 2024
Diana HalimExecutive officerJun 2024
Gun Young Joon ParkExecutive officerJun 2024
Jung In KimExecutive officerJun 2024
Moon Jong NohExecutive officerJun 2024
Soon-Wook Joon KweonExecutive officerJun 2024
Sun Jin Joon KimExecutive officerJun 2024
Yonggyun Joon JeongExecutive officerJun 2024
Young Joon KimExecutive officerJun 2024
Charles Stephen NyeExecutive officerMay 2023
Diana Stephen HalimExecutive officerMay 2023
Gun Young Stephen ParkExecutive officerMay 2023
Jung In Su KimExecutive officerMay 2023
Moon Jong Su NohExecutive officerMay 2023
Sung Su HanExecutive officerMay 2023
Min Seok Su KimExecutive officerDec 2021
Jung In KimDirectorJun 2024
Moon Jong NohDirectorJun 2024
Sun Joo LeeDirectorJun 2024
Jung In Su KimDirectorMay 2023
Moon Jong Su NohDirectorMay 2023
Sun Joo Su LeeDirectorMay 2023
Sung Su HanDirectorMay 2023
Jangik Su LeeDirectorAug 2022
Min Seok Su KimDirectorDec 2021